Psoriatic arthritis: early TNF inhibition achieves remission in more patients

  • van Mens LJJ & al.
  • Ann Rheum Dis
  • 26 Feb 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.


  • Initiation of golimumab (TNF inhibitor) plus methotrexate combination therapy in patients with early, methotrexate-naive psoriatic arthritis was associated with higher number of patients achieving Disease Activity Score (DAS) remission vs placebo+methotrexate.

Why this matters

  • Findings support early intervention in psoriatic arthritis over classical approach.

Study design

  • Double-blind, randomised, placebo-controlled trial.
  • 51 patients were psoriatic arthritis were randomly assigned to golimumab+methotrexate (n=26) or matched placebo+methotrexate (n=25; methotrexate group).
  • Primary endpoint: patients achieving DAS remission (
  • Funding: MSD.

Key results

  • At week 22, 81% of patients with psoriatic arthritis achieved DAS remission with golimumab +methotrexate vs 42% with placebo+methotrexate (P=.004).
  • Patients receiving golimumab+methotrexate reached a Minimal Disease Activity in 81% vs 29% in the methotrexate group (P<.001 disease activity psoriatic arthritis low was achieved in vs>
  • The American College of Rheumatology response criteria 20/50/70 response was achieved by 85%, 81% and 58%, respectively, in the golimumab+methotrexate vs 58%, 33% and 13%, respectively, in the methotrexate group (P=.039, .001 and .001, respectively).
  • The rates of adverse event and treatment emergent adverse event were similar in both arms.


  • Magnetic resonance imaging or ultrasound was not included to evaluate the presence or absence of active synovitis or enthesitis.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.